(Ga 68 DOTATOC®)


Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 18.5 MBq/mL to 148 MBq/mL [0.5 mCi/mL to 4 mCi/mL])
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies


  • Indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ga 68 DOTATOC is indicated for use with positron emission tomography (PET) for localizing somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. It has shown superior sensitivity compared to SPECT agents, making it more suitable for in vivo identification of these tumors.
  • The study synthesized findings from a total of 10 systematic reviews and meta-analyses on the use and application of Ga 68 DOTATOC.
  • In comparison to other tracers such as I-131 MIBG and chemotherapy, Ga 68 DOTATOC demonstrated favorable disease control rates, especially in paragangliomas (PGLs), pheochromocytomas (PCCs), meningiomas, and tumor-induced osteomalacia (TIO). However, hematologic toxicity was identified as a secondary concern.
  • For recurrent meningiomas and pituitary carcinomas cases, the use of SSR-targeted PET with Ga 68 DOTATOC enhances diagnostic accuracy while improving radiotherapy planning. This also confirms patient eligibility for PRRT treatment but calls attention to clearer management guidelines due to variations observed across studies.
  • Genetic alterations like mutations of SDHB were frequently observed among populations affected by PCCs & PGLs, which could influence treatment responses. Also noted was that advanced or inoperable NET patients showed substantial benefit from Lu-DOTATATE/DOTATOC PRRT treatments, indicating the importance based on disease severity considerations during the treatment selection process.
  • Ga 68 DOTA-SSTR PET/CT exhibited higher sensitivity than F18 FDG PET/CT when detecting Tumor Induced Osteomalacia(TIO). Therefore, it should be considered as the first-line imaging modality over others.

Product Monograph / Prescribing Information

Document TitleYearSource
Ga 68 DOTATOC Prescribing Information.2021UIHC PET Imaging Center, Iowa City, IA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis.2023Journal of Clinical Medicine
Head-to-head comparison between peptide-based radiopharmaceutical for PET and SPECT in the evaluation of neuroendocrine tumors: a systematic review.2022Current Issues in Molecular Biology
Somatostatin receptor targeted pet-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: a systematic review of the literature.2022Diagnostics
The role of [68Ga]Ga-DOTA-SSTR PET radiotracers in brain tumors: a systematic review of the literature and ongoing clinical trials.2022Cancers
Diagnostic utility of Ga-68 DOTA-SSTR and F-18 FDG PET/CT in the detection of culprit tumours causing osteomalacia: a systematic review and meta-analysis.2021Nuclear Medicine Communications
Performance of 68Ga-DOTA–conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis.2020Journal of Nuclear Medicine
Comparison of gallium-68 somatostatin receptor and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of neuroendocrine tumours: a systematic review and meta-analysis.2020Hellenic Journal of Nuclear Medicine
Somatostatin receptor PET/CT imaging for the detection and staging of pancreatic NET: a systematic review and meta-analysis.2020Diagnostics
The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: a meta-analysis.2020Medicine Open
Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide pet in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis.2019Journal of Nuclear Medicine

Clinical Practice Guidelines